AstraZeneca stock sinks after FDA advisers vote against its breast cancer drug May 01, 2026 · Colleen Cabili An FDA advisory committee voted 6-3 against camizestrant, citing concerns about the trial design and whether patients benefit long-term Read more »
.jpg?branch=production&format=jpg&width=1024)
.jpg?branch=production&format=jpg&width=1024)
.png?branch=production&format=jpg&width=1024)
